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Genetic mechanisms underlying age-related cognitive decline and dementia remain poorly understood.
Here, we take advantage of the Diversity Outbred mouse population to utilize quantitative trait loci mapping
and identifyDlgap2 as a positional candidate responsible for modifyingworkingmemory decline. To evaluate
the translational relevance of this finding, we utilize longitudinal cognitive measures from human patients,
RNA expression from post-mortem brain tissue, data from a genome-wide association study (GWAS) of Alz-
heimer’s dementia (AD), and GWAS results in African Americans.We find an association betweenDlgap2 and
AD phenotypes at the variant, gene and protein expression, and methylation levels. Lower cortical DLGAP2
expression is observed in AD and is associated with more plaques and tangles at autopsy and faster cogni-
tive decline. Results will inform future studies aimed at investigating the cross-species role ofDlgap2 in regu-
lating cognitive decline and highlight the benefit of using genetically diverse mice to prioritize novel candi-
dates.
INTRODUCTION
Aging is the leading risk factor for a number of disorders,
including dementias such as Alzheimer’s disease. The mecha-
nisms that underlie healthy aging—particularly, the cognitive as-
pects—remain poorly understood. Research suggests that ge-
netics play a significant role in determining an individual’s
susceptibility or resilience to cognitive decline and dementia
(Harris and Deary 2011; Ridge et al., 2013). Identification of pre-
cise genetic factors involved would provide insight into
Cell Reports 32, 108091, September 1, 2020 ª 2020 The Author(s). 1
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ll
OPEN ACCESS
Figure 1. Dlgap2 Mediates Cognitive Function across the Lifespan in DO Mice
(A) Diversity Outbred (DO) mice are a genetically diverse population derived from 8 parental lines, segregating for a total of 40 million single nucleotide poly-
morphisms (SNPs).
(legend continued on next page)




mechanisms underlying increased susceptibility and uncover
therapeutic targets.
The mouse represents a critical resource to identify genetic
factors influencing complex traits due to well-defined genetic
backgrounds, well-controlled environmental conditions, and
lower sample size requirements for genetic mapping than human
populations. Recent efforts to expand the genetic resources
available in the mouse have resulted in the development of the
Diversity Outbred (DO) panel (Churchill et al., 2012; Logan
et al., 2013), which is derived from an 8-parent population segre-
gating approximately 40 million variants (Srivastava et al., 2017).
The resulting offspring provide precision and power for genetic
analysis of complex traits such as cognitive decline in aging.
Here, we perform a large-scale, cross-sectional evaluation of
cognitive performance in the DO population aged 6 to 18months
and identify a single protein-coding positional candidate (disk-
associated large protein 2, Dlgap2) likely mediating observed
age-related decline. Across a subset of DO mice, we find that
morphologic variation among dendritic spine populations signif-
icantly correlates with cognitive outcomes. AsDlgap2 is a critical
component of spines (Jiang-Xie et al., 2014), this finding pro-
vides an avenue for future mechanistic investigation into the
observed association between Dlgap2 and cognitive decline.
Finally, we demonstrate that Dlgap2 is associated with cognitive
decline and Alzheimer’s dementia (AD) in diverse human popula-
tions. Results highlight the utility of the mouse to (1) inform
studies in human patients and (2) enable prioritization of genes
and variants for further study.
RESULTS
Dlgap2 Mediates Cognitive Longevity in DO Mice
To identify genes involved in regulating the maintenance of
cognitive function during aging, working memory was evaluated
on the T-maze (Wenk, 2001) at 6, 12, or 18 months in 487 DO
mice (Figure 1A). Working memory declined with age, F(2,
484) = 2.8, p = 0.03, one-tailed (Figure 1B). No effect of sex
was observed on working memory performance, F(1, 484) =
0.02, p = 0.90. To identify genetic factors regulating working
memory, we next performed genetic mapping. A quantitative
trait locus (QTL) on chromosome 8 (chr8) (Figure 1C) that inter-
acted with age to mediate working memory performance across
the lifespan (LOD = 12.5, 1.5 LOD interval = 14.3–14.6 Mb, p <
0.05) was identified. Allelic coefficient plots demonstrate that,
at 6 months of age, the non-obese diabetic (NOD) background
contributes a lower working memory score, while the 129 and
B6 backgrounds contribute higher working memory scores (Fig-
ure 1D, top). Age interactions with this locus were largely driven
by NOD, B6, and 129 at 12 months of age (Figure 1D, top; Fig-
ures S1A and S1B). We also see age interactions across the
QTL haplotype region (Figure S1C). A single protein-coding
gene, Dlgap2, is located within the QTL interval (Figure 1D, bot-
tom), highlighting Dlgap2 as the most likely positional candidate
mediating working memory decline as a function of aging. SNP
association tests within the QTL region using the most up-to-
date Sanger sequencing information identified one high-confi-
dence SNP and a single structural variant that differed between
NOD and 129 within the intronic regions of the Dlgap2 gene
(Figure S1D).
Dlgap2 is a critical component of the postsynaptic density
involved in regulating synaptic function and dendritic spine
morphology (Li et al., 2017). Given studies linking structural alter-
ations in dendritic spinemorphology with age-related changes in
cognitive function (Dickstein et al., 2013; Dumitriu et al., 2010;
Boros et al., 2019), wemeasured the number and functional sub-
types of spines in the hippocampus in a subset of DO mice at 6,
12, or 18 months of age (Figure 1E). We observed no changes in
total spine density or distribution of spine type (thin, stubby, or
mushroom; Table S1) with age. Neither spine density nor spine
type correlated with cognitive outcomes at 6 or 12 months of
age (Figure S2). However, by 18 months, there was a significant
correlation between both the percentage of thin and stubby
spines and working memory performance (Figures 1F–1H), sug-
gesting that maintenance of high numbers of thin spines com-
bined with lower numbers of stubby spines is beneficial for main-
taining cognitive function during aging (Dumitriu et al., 2010).
Genetic Variants in the DLGAP2 Region Are Associated
with AD
We next sought to test the translational relevance of this finding
by evaluating the association of DLGAP2 with clinically diag-
nosed dementia in human populations. We evaluated SNPs
within the DLGAP2 region (±50 kb) within published and pending
genome-wide association studies (GWASs) of clinical Alz-
heimer’s disease. Among individuals with European ancestry
(Jansen et al., 2019), one locus just downstream of DLGAP2
was associated with AD: top SNP, rs2957061; p = 3.6 3 105;
b =0.02; odds ratio (OR) = 0.98; Figure S3A, Table S2). Among
African American individuals, a locus within DLGAP2 was asso-
ciated with AD: top SNP, chr8:1316870; minor allele frequency
(MAF) = 0.01; p = 9.2 3 105; b = 0.86, OR = 0.42; Figures
2A and S3B; Table S3).
(B) Working memory was assessed on the T-maze at 6, 12, or 18 months across 487 DOmice (6 months, 66 female mice [F]/67 male mice [M]; 12 months, 102 F/
96 M; and 18 months, 76 F/80 M), and a significant effect of age was observed; one-way ANOVA, F(2, 484) = 2.8, p = 0.03, one-tailed. Red line represents the
mean of displayed data.
(C) A quantitative trait locus (QTL) on chr8 was identified that significantly interacted with age tomediate workingmemory performance across the lifespan (LOD =
12.5; 1.5 LOD interval = 14.3–14.6 Mb). Dashed line indicates permutation-based cutoff of suggestive QTL, p = 0.20. Red line indicates permutation-based cutoff
for significant QTL, p = 0.05.
(D) Top: coefficient plots indicated according to the color key by founder allele illustrate the impact of each allele on working memory phenotype at 6, 12, and
18 months of age. Bottom: a single protein-coding gene, Dlgap2, is located within the QTL interval, along with a number of regulatory elements.
(E) Spine number and morphology were assessed in CA1 hippocampal pyramidal neurons. Scale bar, 10 mm.
(F and G) Across 18-month-old DO mice, significant correlations between (F) working memory function and percentage of thin spines and (G) percentage of
stubby spines was observed.
(H) No association between percentage of mushroom spines and working memory was observed.
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A previous GWAS (White et al., 2017) reported that
rs34130287C, a SNP within the first intron of DLGAP2, was sug-
gestively associated with worse residual cognition (p = 4.0 3
106), a trait that quantified the gap between observed and pre-
dicted cognitive performance after regressing out the effect of
neuropathology. DLGAP2 was not pursued as a potential candi-
date because NCBI and Ensembl annotations, at the time of the
prior report, did not include rs34130287C within DLGAP2. How-
ever, as of February 2019, current annotations place this SNP
within DLGAP2. Using the same dataset and methods as initially
reported (White et al., 2017), we observed a significant relation-
ship between the overall methylation pattern of the DLGAP2 re-
gion in the dorsolateral prefrontal cortex (DLPFC) and residual
cognition (p = 0.038; Figure S3C). As methylation at the DLGAP2
locus has been shown to influence Dlgap2 expression in mouse
(Chertkow-Deutsher et al., 2010), we hypothesize that the effect
of this locus on cognitive function is mediated by alterations in
Dlgap2 expression in the DLPFC.
Expression of DLGAP2 Is Associated with Cognitive
Decline in Human Populations
We next sought to test this hypothesis by evaluating the associ-
ation of DLGAP2 with cognitive function and dementia in human
populations. Across the Religious Orders Study and the Rush
Memory and Aging Project (ROS/MAP), lower levels of DLGAP2
mRNA in the DLPFC of post-mortem human brain tissue were
associated with poorer cognitive performance at the final visit
prior to death (b = 0.10, p = 0.01) and faster cognitive decline
over all study visits (b = 0.01, p = 0.002; Figure 2B). This relation-
ship was strongest among individuals with clinically diagnosed
AD (Figure 2C). When assessing protein levels of DLGAP2
measured with tandem mass tag mass spectrometry (Johnson
et al., 2020), we observed a consistent finding with lower levels
of DLGAP2 protein associated with a faster rate of cognitive
decline (b = 0.29, p < 0.001; Figure S3D).
DLGAP2 Is Differentially Expressed in Brains of Those
with Cognitive Impairment
To assess differences in DLGAP2 expression during various
stages of cognitive impairment, we evaluated DLPFC mRNA
expression of DLGAP2 across ROS/MAP. Those with mild
cognitive impairment (MCI) and clinically diagnosed AD had
lower levels of expression compared to patients with normal
cognition, F(2, 528) = 4.4, p = 0.01 (Figure 2D). A similar decrease
of DLGAP2was observed in two independent datasets covering
5 brain regions (Table S4), strengthening our confidence in these
findings. As DLGAP2 is a component of synapses (Li et al., 2017)
and highly correlated with expression of the neuronal marker
ENO2 (Figure 2E, left), it is possible that this decrease ofDLGAP2
is due to neurodegeneration that occurs in MCI and Alzheimer’s
disease. However, when considering only neuronal expression
data from laser-capture microdissected neurons (Liang et al.,
2008) to control for number of neurons evaluated, a significant
decrease in DLGAP2 remained (Figure 2E, right). This suggests
that reducedDLGAP2 occurs independent of frank neurodegen-
eration. While not associated with neurodegeneration, we next
evaluated whether DLGAP2 was associated with other neuro-
pathological hallmarks of Alzheimer’s disease measured with
immunohistochemistry (IHC). Lower levels of DLGAP2 were
associated with greater b-amyloid load in the DLPFC (b =
0.13, p = 0.002). Similarly, lower levels of DLGAP2 were asso-
ciated with more neurofibrillary tangles in the DLPFC (b =0.11,
p = 0.02). No associations were observed with non-Alzheimer
neuropathologies (Table S5; p values > 0.10).
DISCUSSION
Utility of DO Mice for Cross-Species Analyses
Despite the recent increase in availability and accessibility of
genomic technologies, our understanding of the genetic mech-
anisms underlying complex traits remains poor. This is due, in
part, to the difficulty in assigning causality to GWAS hits, a
number of which occur in non-coding regions of the genome
(Zhang and Lupski 2015). For example, the two loci highlighted
here (Figures 2A and S3A) fall within complex genomic regions,
making the biological mechanism driving the observed associ-
ations difficult to interpret. However, by combining these re-
sults with studies performed in the mouse, we not only identify
Dlgap2 as a potential causal gene in the region but also high-
light structural plasticity and modification of spine type (Figures
1E–1H) as a mechanism putatively involved in modifying cogni-
tive decline.
An additional factor complicating the identification of disease-
causative genes using GWAS is a lack of statistical power,
particularly in under-represented populations where sample
size is relatively limited (Popejoy and Fullerton 2016). As a result,
population-specific genetic mechanisms underlying diseases,
and treatments that may prevent or cure them, remain undiscov-
ered. To better inform population-specific analyses, mouse
studies offer a powerful way to prioritize candidates. In
Figure 2. DLGAP2 Is Associated with Cognitive Function and Alzheimer’s Disease in Diverse Human Populations
(A) An SNP located at chr8: 1316870 (MAF = 0.01) was modestly associated with AD within a GWAS of African American individuals (p = 9.2 3 105). Current
Ensembl annotation (as of February 2019, release 95; data not shown) places this SNP within the first intron of DLGAP2.
(B) Across the ROS/MAP cohort, higher levels of DLGAP2 in the dorsolateral prefrontal cortex (DLPFC) were associated with slower annual cognitive decline
(b = 0.01, p = 0.002).
(C) This association was strongest among patients clinically diagnosed with AD. Normal cognition (NC): n = 180, b = 0.02, p = 0.43; mild cognitive impairment
(MCI): n = 148, b = 0.04, p = 0.18; AD: n = 203, b = 0.08, p = 0.16.
(D) DLGAP2 expression was significantly lower in the DLPFC of participants diagnosed with either MCI or clinical AD relative to NC, F(2, 528) = 4.4, p = 0.01.
(E) Left: correlation of DLGAP2 and cell-type-specific markers ENO2 (neurons), OLIG2 (oligodendrocytes), GFAP (astrocytes), CD68 (microglia), and CD34
(endothelial cells) as measured by RNA expression from DLPFC tissue across the ROS/MAP cohort. Right: expression of DLGAP2 is decreased specifically in
neurons from AD patients, as measured by RNA expression from laser-capture microdissected neurons from Liang et al. (2008); p < 0.05. Boxes encompass the
25th to 75th percentile with whiskers indicating 10th and 90th percentiles. Median lines are indicated within each box.




particular, the DO population provides an advantage over previ-
ous genetically diverse resources, including a higher degree of
genetic diversity and smaller haplotype blocks, leading to more
precise genomic mapping (Churchill et al., 2012). A caveat to
this increased genetic diversity is the large number of allelic com-
binations present at any given locus. Although the present study
was not sufficiently powered to estimate all heterozygous allelic
combinations driving the effects, we were still able to identify
founder effects in an eight-state additive model. By doing so,
our mapping strategy nominated only one protein coding gene
with well-known functions in regulating synaptic throughput,
structure, and function (Jiang-Xie et al., 2014; Chertkow-
Deutsher et al., 2010), highlighting the importance of this biolog-
ical pathway to working memory. Although it is possible that
these variants play a role in distal gene regulation, other sources
of evidence supported our decision to move forward with
DLGAP2 as a top candidate for tests in human cohorts. This
was based on combining our interactive mapping result high-
lighting Dlgap2, biological priors (Jiang-Xie et al., 2014), and
our finding that variation in spine type is correlated with memory
outcomes in aging DOmice that is consistent with findings in hu-
man studies (Boros et al., 2017). Overall, candidate genes nomi-
nated by studies in the DO have the potential to greatly
contribute to the understanding of mechanisms underlying com-
plex traits in both mouse and humans.
Dlgap2 and Cognitive Decline
Here, we show that reduced Dlgap2 is associated with faster
cognitive decline, AD and disease diagnosis, and increased
neuropathology in humans across multiple brain regions and in-
dependent datasets. We also provide evidence that DLGAP2
protein abundance in brain is associated with cognitive decline.
Mutant mice that lack Dlgap2, a post-synaptic density scaf-
folding protein, show impaired initial reversal learning, deficits
in synaptic communication, and reduced dendritic spine den-
sity (Jiang-Xie et al., 2014). Spine loss correlates more strongly
to cognitive decline in Alzheimer’s disease than the classical
neuropathological hallmarks (Dorostkar et al., 2015; Boros
et al., 2017; DeKosky and Scheff 1990; Terry et al., 1991). How-
ever, mechanisms underlying this loss of spines are still poorly
understood. Work here suggests aging mouse models—at
least the DO population, in particular—may provide an impor-
tant experimental system in which to begin to understand
mechanisms contributing to spine loss and cognitive dysfunc-
tion in human populations. Notably, the spine phenotypes
that correlate to working memory in our DO population mimic
the increase in thin spine density and simultaneous reduction
in stubby spines observed exclusively in patients that exhibited
cognitive resistance to Alzheimer’s disease pathology (Boros
et al., 2017, 2019). As we know, genotype at Dlgap2 plays an
important role in regulating cognitive decline in the DO popula-
tion (Figure 1D), and Dlgap2 critically regulates spine number
and morphology (Jiang-Xie et al., 2014). Therefore, we hypoth-
esize that Dlgap2 may act as a potential driver of cognitive
decline and later transition to dementia via its role in mediating
spine-related phenotypes. This hypothesis will need to be
experimentally tested, although the work here provides an
important starting point for future mechanistic studies focused
on elucidating the role of Dlgap2 in cognitive decline across
species.
Conclusions and Future Directions
In summary, the work here identifies Dlgap2 as a potential medi-
ator of cognitive decline in both mouse and humans and high-
lights the benefit of using genetically diverse mouse populations
to inform mechanistic studies and identify novel candidates
involved in complex human disease. Future studies will investi-
gate the role of identified variants, precise molecular mecha-
nisms involved in mediating cognitive decline, and the utility of
Dlgap2 as a therapeutic target to promote healthy brain aging.
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Catherine
C. Kaczorowski (catherine.kaczorowski@jax.org).
Materials Availability
Diversity outbred mice used in this study are currently available from the Jackson Laboratory (https://www.jax.org/strain/009376),
JAX#009376. This study did not generate new unique reagents.
Data and Code Availability
The accession number for the summary-level data from a harmonized differential gene expression analysis completed by the Accel-
erating Medicines Partnership Alzheimer’s Disease project is AMP-AD Knowledge portal:syn14237651 (https://www.synapse.org/#!
Synapse:syn14237651).
The accession number for the data from the MayoRNaseq study is:AMP-AD Knowledge portal: syn5550404 (https://www.
synapse.org/#!Synapse:syn5550404). The accession number for the Mount Sinai Brain Bank (MSBB) study is AMP-AD Knowledge
Portal: syn3159438 (https://adknowledgeportal.synapse.org/Explore/Studies/DetailsPage?Study=syn3159438). The accession
number for the RNA expression from laser-captured micro-dissected neurons is GeneNetwork.org: GN Accession #233
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Critical Commercial Assays
RNeasy Lipid Tissue Mini Kit QIAGEN Cat#74804



















African American GWAS https://www.niagads.org/datasets/ng00100 ID NG00100
Experimental Models: Organisms/Strains
Mouse: Diversity Outbred (J:DO) The Jackson Laboratory JAX # 009376
Software and Algorithms
R/qtl2 Broman et al., 2019 https://kbroman.org/qtl2/
Ethovision Noldus Information Technology https://www.noldus.com/
Fiji-ImageJ Schindelin et al., 2012 https://imagej.net/Fiji
Imaris Oxford Instruments https://imaris.oxinst.com/
METAL Willer et al., 2010 https://sph.umich.edu/csg/abecasis/metal/
BeadStudio Illumina https://www.illumina.com/
GWAF Chen and Yang, 2010 http://www2.uaem.mx/r-mirror/web/
packages/GWAF/GWAF.pdf




(http://gn1.genenetwork.org/webqtl/main.py?FormID=sharinginfo&GN_AccessionId=233). The accession number for the summary
statistics for African American GWAS is NIAGADS: NG00100 (https://www.niagads.org/datasets/ng00100).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Diversity Outbred (J:DO) mice were obtained from The Jackson Laboratory via the Nathan Shock Center of Excellence in the Basic
Biology of Aging. All mice were part of a cross-sectional phenotyping project in which independent cohorts of mice were timed for
nearly simultaneous testing of 6, 12 and 18 month old mice to avoid repeated testing. The sample sizes for each group were as
follows: 6 m = 66F/67M, 12 m = 102F/96M, 18 m = 76F/80M. Mice were genotyped using the MegaMUGA array (GeneSeek, Lincoln,
Nebraska) and genotype probabilities estimated using R/DOQTL (Gatti et al., 2014). Mice were housed in duplex polycarbonate
cages on ventilated racks providing 99.997% HEPA filtered air to each cage in a climate-controlled room under a standard 12:12
light-dark cycle (lights on at 0600 h). Singly housed mice were provided with enrichment in the form of a Shepherd Shack. All exper-
iments were performed during the light phase of the light/dark cycle. Pine bedding was changed weekly and mice were provided
ad-libitum access to food (NIH31 5K52 chow, LabDiet/PMI Nutrition, St. Louis, MO) and acidifiedwater. All procedures and protocols
were approved by The Jackson Laboratory Animal Care and Use Committee, and were conducted in compliance with the National
Institutes of Health Guidelines for the Care and Use of Laboratory Animals.
METHOD DETAILS
Behavioral testing
Behavioral testing was performed during the light phase of a 12:12 light/dark cycle. The spontaneous continuous alternation T-maze
test was performed using the Med Associates
(St. Albans, VT) mouse maze (MED-TMMN) with 3 arms placed at 90 degrees to one another on an octagonal hub. The maze was
situated in the center of a 10 ft. x 10 ft. room. Large (approximately 24 inch) distinct visual cues comprising geometric shapes made
from self-adhesive vinyl were on the surrounding walls. Mice were transferred from the housing room to the testing room via a whee-
led cart and allowed to habituate for at least 60 minutes prior to testing. Mice were removed from the cage one at a time for the maze
trial and returned to the home cage after testing. Mice were placed into an enclosed arm of the T-maze and after 10 s the guillotine
door was lifted and themousewas allowed to explore freely for the remainder of the 5min trial. The trials were recorded using a single
overhead camera and videos were tracked automatically using Noldus Ethovision V7 (Wageningen, NL) to determine time spent in
each arm. The center point of themouse was used to determinemouse position at a rate of 29.9 frames per second. Post-processing
to calculate number of transitions and the percent of correct alternations were calculated using the Sequence Analysis Tool (SAT), an
Excel macro provided by Noldus Ethovision designed to calculate zone transitions and analyze sequences of arms visited. In a cor-
rect alternation mice visit all three arms before reentering a previously visited arm. Errors include repeat visits to a single arm within
the previous three arms visited, or failure to visit all three arms. Mice who avoid an arm completely over the duration of the trial are
omitted from analysis. Time spent in each arm, number of transitions, and the percent of correct alternations were calculated.
Genetic mapping
Genetic mapping was conducted using R/qtl2 (qtl2geno, qtl2scan, and qtl2plot packages) to perform single quantitative trait loci
(QTL) scans with sex and age as covariates (Broman et al., 2019). To identify QTL that interact with age and play a role in regulating
cognitive decline, age was also included as an interactive covariate. Results (i.e., LOD scores) from the additive scans were sub-
tracted from results from the interactive scans to identify QTL that uniquely interacted with age and were not present in the
additive model. Permutation tests were used in each case to evaluate significance. For simple additive and interactive scans,
1000 standard permutations were performed. For evaluating significance for the interactive-minus-additive scans (Figure 1C, bot-
tom), permutations were performed as follows: First, genotypes and phenotypes are permuted identically across interactive and
additive models. Genome-wide scans for each model were performed 1000 times, with genotype/phenotype randomization occur-
ring differently for each permutation, but kept the same between additive/interactive scans. For each permutation the additive LOD
scores were subtracted from the interactive; the maximum LOD score of these differentiated peaks was recorded. From the distri-
bution of 1000 maximum LOD scores, the score in the 95th percentile (alpha = 0.05) was selected and used as the significance
threshold for interactive-additive difference QTL map. QTL that exhibit a higher difference score than this significance threshold
are said to significantly interact with age to determine working memory performance (Broman and Sen, 2009; Broman et al.,
2019). These QTL represent particularly interesting loci, as genotype at these locations putatively interact with age tomediate decline
over time, rather than just confer high cognitive reserve and good cognitive performance across the lifespan (Broman and Sen, 2009).
Spine analysis
At the completion of all phenotyping including physiological testing, mice were decapitated to preserve brain tissue and brains
removed. The brain was hemisected, and the right hippocampus was saved for RNA analysis and the left hemisphere was used
for diolistic labeling and dendritic spine analyses. The brain was hemisected using 2 single edge stainless steel razor blades. Blades
are cleaned between mice and replaced every 4 mice.




The left hemisphere was placed in 5 mL 4% PFA in PBS for 1 hr. After 1 hr., the sample was moved into 4 mL 1x PBS at room
temperature and stored at 4C overnight. Within several days the brains were sliced in the coronal plane in the brain matrix and
150 um sections were obtained using a vibratome. The sections were placed in PBS in 6 well plates. A Helios gene gun was
used to label the sections with DiI-coated tungsten beads. The samples were left in the dark at room temperature overnight. After
24 hours the sections were post-fixed in 4%PFA for one hour. The slices were then counter-stained with DAPI andmounted on slides
using Dako anti-fade mounting medium and the slides were stored at 4C in the dark until confocal imaging was completed. A Leica
SP5 or SP8 confocal microscope was used to obtain a 20x z stack at 1 um step size of the whole neuron and a 63x glycerol im-
mersion z stack of secondary dendritic branches for spine analysis. One pyramidal neuron of the CA1 region of the hippocampus
was imaged for each mouse. To be analyzed, dendrites must have been a minimum of ten micrometers in length. The analysis
was completed by a blind observer, with no knowledge of the mouse’s age group or performance on behavioral tests.
The image analysis consisted of quantifying dendrite length, spine count, spine density, and spine morphology using Fiji ImageJ
(Schindelin et al., 2012) and the FilamentTracer module in Imaris software. The Classify Spines feature was used to categorize spine
types.
Human study participants
To validate the translation relevance of candidate genes associated withmemory performance in DOmice, data and summary results
were obtained from a number of well-defined studies of cognitive aging and Alzheimer’s dementia (AD). First, gene level results were
assessed leveraging data from two cohort studies of cognitive aging, The Religious Orders Study (ROS) and The Rush Memory and
Aging Project (MAP). Both studies enrolled participants free of dementia who agreed to annual clinical evaluations and brain donation
at death (Bennett et al., 2012a, 2012b, 2018). Informed consent and an Anatomical Gift Act for organ donation was obtained from all
participants, participants signed a repository consent for resource sharing, and all research adhered to individual Institutional Review
Board (IRB)-approved protocols.
Second, data from the MayoRNaseq study (https://www.synapse.org/#!Synapse:syn5550404) and the Mount Sinai Brain Bank
(MSBB) study (https://adknowledgeportal.synapse.org/Explore/Studies/DetailsPage?Study=syn3159438) were leveraged for repli-
cation of differential expression results from ROS/MAP. In the Mayo study, post-mortem samples were collected from the temporal
cortex and cerebellum, as previously described (Allen et al., 2016, 2018). In the MSBB study, post-mortem samples were collected
from the inferior frontal gyrus, frontal pole, parahippocampal gyrus, and superior temporal gyrus as previously described (Wang et al.,
2018).
Finally, we leveraged summary statistics from a recently published GWAS of AD among individuals of European Ancestry (Jansen
et al., 2019) and in African American participants (B.W.K., M. Schmidt, H.-U. Klein, A.C. Naj, K.L. Hamilton-Nelson, and C.R., unpub-
lished data). Given the most up-to-date African American GWAS of AD, additional details are provided below. All human analyses
were completed using RStudio (version 1.1.453; https://rstudio.com/) with R version 3.3.1.
African American GWAS Analysis: Sample Characteristics
A GWAS meta-analysis was completed leveraging data from 8084 African American individuals who were 60 years of age or older
(2838 cases, 5246 controls, 69% female). Clinical diagnosis of ADwas established using standard procedures within each study site,
protocols have been published previously (Reitz et al., 2013).
Genotype quality control and imputation
Standard quality control for genotype and sample-level data was conducted individually for each dataset. Single-nucleotide poly-
morphisms with call rates less than 98% or not in Hardy-Weinberg equilibrium (p < 106 in controls) were excluded. Individuals
with non-African American ancestry according to principal components (PCs) analysis of ancestry informative markers were
excluded, as were participants whose reported sex differed from the sex assignment determined by analysis of the X chromosome
SNPs. Latent relatedness among participants within and across the case-control cohorts was identified by the estimated proportion
of alleles (p) shared identical by descent (IBD). One participant from each duplicate pair (p > 0.95) or relative pair (0.4%p < 0.95) was
included in the sample used for association analyses, prioritizing based on non-missing disease status and then higher SNP call rate.
After genotype quality control, all datasets were individually phased and SNPs were imputed with the African Genome Resource
(AGR) using the Sanger Imputation Service (https://www.sanger.ac.uk/tool/sanger-imputation-service/). Common variants (minor
allele frequency [MAF] R 0.01) with imputation quality score < 0.4, rare variants (MAF < 0.01) with imputation quality < 0.7, and
variants present in less than 30% of AD cases and 30% of controls across all datasets were excluded from downstream analyses.
Human genome build GRCh37 was used.
Association analysis
Single variant association analysis was performed on genotype dosages using an additive model adjusting for age, sex, and PCs. For
case-control datasets, we employed logistic regression, while family-based datasets used generalized estimating equations (GEE)
as implemented in GWAF (Chen and Yang 2010). Within-study results were meta-analyzed using an inverse-variance based model
with genomic control as implemented in METAL (Willer et al., 2010).




Differential gene expression analysis in humans
In ROS/MAP, RNA expression levels were obtained from frozen, manually dissected dorsolateral prefrontal cortex (DLPFC) tissue
(Lim et al., 2014). Isolation of RNA was performed using the RNeasy lipid tissue kit (QIAGEN, Valencia, CA) and it was reverse tran-
scribed using the Illumina TotalPrep RNA Amplification Kit from Ambion (Illumina, San Diego, CA). Following sequencing, process-
ing of the expression signals was performed using the BeadStudio software suite (Illumina, San Diego, CA). Standard normalization
and quality control methods were then employed (Lim et al., 2014). Differential expression of DLGAP2 between individuals with AD
and individuals with normal cognition prior to death was assessed using linear regression, covarying for age at death and sex. Sum-
mary-level data from a harmonized differential gene expression analysis completed by the Accelerating Medicines Partnership
Alzheimer’s Disease project (https://www.synapse.org/#!Synapse:syn14237651) was used for replication in Mayo and MSSM.
Additionally, RNA expression from laser-captured micro-dissected neurons described previously (Liang et al., 2008) was utilized
via GeneNetwork.org (GN Accession: #233) to assess cell-type specific changes of DLGAP2 expression.
Gene expression associations with neuropathologies of age-related disease
Neuropathological measures available in ROS/MAP have been described in detail previously (Bennett et al., 2012a, 2012b). For the
present analyses, we utilized previously collectedmeasures of phosphorylated tau and b-amyloid quantified with immunohistochem-
istry (IHC). The percentage of area occupied by b-amyloid or tau averaged across 8 brain regions (hippocampus, angular gyrus, and
entorhinal, midfrontal, inferior temporal, calcarine, anterior cingulate, and superior frontal cortices). Associations between DLGAP2
mRNA levels and b-amyloid plaques and tau tangles were assessed using linear regression covarying for age at death and sex. Out-
comes were square-root-transformed to better approximate a normal distribution.
Additional semiquantitative measures included TDP-43 pathology, cerebral amyloid angiopathy (CAA), atherosclerosis, arteriolo-
sclerosis, gross infarctions, micro infarctions, and Lewy bodies. Details of the measurement and quantification for these methods
have been published previously but are also summarized here. Six brain regions (amygdala, hippocampus CA1, dentate gyrus, en-
torhinal, midtemporal, and midfrontal cortices) were stained with monoclonal phosphorylated TDP-43 antibodies to obtain a score
from 0 (indicating absence of pathology) to 4 (indicating presence of pathology in all regions) (Amador-Ortiz et al., 2007). CAA was
measured in the midfrontal, midtemporal, parietal and calcarine cortices and the burden of pathology was summarized with a score
from 0 (no deposition) to 3 (severe deposition) across the regions (Boyle et al., 2015). Circle of Willis vessels were visually inspected
for atherosclerosis which was quantified by a score from 0 (no significant atherosclerosis) to 3 (over half had atherosclerosis or at
least one had 75% occlusion or both) (Arvanitakis et al., 2017). Severity of arteriolosclerosis was classified into 4 levels, 0 indicating
no histological changes and 3 indicating severe changes (Buchman et al., 2011). Nine regions (midfrontal, midtemporal, entorhinal,
hippocampal, inferior parietal and anterior cingulate cortices, anterior basal ganglia, thalamus, and midbrain) were examined to
determine the presence or absence of gross and microinfarctions. Gross infarctions were identified by visual inspection and
confirmed histologically. Micro infarctions were identified by inspection of 6 mm hematoxylin/eosin stained paraffin-embedded sec-
tions of each region (Arvanitakis et al., 2017; Schneider et al., 2003, 2007). Lewy body disease wasmeasured in sections from eight of
the nine brain regions mentioned above (not the thalamus) by a-synuclein immunostaining and coded as 0 (not present), 1 (nigral-
predominant), 2 (limbic-type), or 3 (neocortical-type) (Schneider et al., 2012). All associations with these outcomes were assessed
using binary logistic regression or proportional odds models covarying for age at death and sex.
Analysis of DLPFC gene expression associations with longitudinal cognition in humans
Cognitive function was quantified into a single composite measure generated by averaging the z-scores of 17 cognitive tests that
spanned 5 domains of cognitive function (episodic, semantic, and working memory, perceptual orientation, and perceptual speed)
(Wilson et al., 2015). For this measurement, a negative score is indicative of worse cognitive performance over time. Longitudinal
associations between DLGAP2 expression and global cognition in ROS/MAP were tested using mixed-effects regression. Age at
death, sex, gene expression level, latency to death (time between final visit and death), interval (years between neuropsychological
visit and final visit prior to death), and an interval x gene expression interaction term were considered fixed effects. The intercept and
interval were additionally entered as random effects in the model.
Analysis of DNA methylation in DLPFC
A residual cognition scorewas calculated as previously described (White et al., 2017), in which lower scores represent lower cognitive
performance than predicted given the level of neuropathology present in the brain. Specifically, residual cognition was captured by
regressing out the effects of cerebral pathologies (including Alzheimer’s disease pathology, cerebrovascular pathologies, Lewy
bodies, and hippocampal sclerosis) and demographic characteristics (age at death, sex, years of education, and study cohort)
from global cognitive performance proximate to death.
DLPFC DNA methylation was measured as previously described (De Jager et al., 2014). For the present analysis we defined the
DLGAP2 region as the chromosomal region that includes the gene and its flanking 100 kb at the 50 and 30 ends, according to the NCBI
Homo sapiens annotation release 109 and Ensemble release 95 (hg19: Chr 8, from 777021 bp through 1756642 bp). There were 798
CpGs within this region. In 648 ROS/MAP participants with non-missing data, we assessed the association between residual
cognition and the overall methylation pattern of the DLGAP2 region using the previously described method (White et al., 2017). In




brief, we first assessed the association between each CpG (independent variable) and residual cognition (dependent variable), con-
trolling for technical variables, and derive an observed test statistic from the p values using Fisher’s method:
Test statistic = 
X
log10pCpG
Then, by permuting the dependent variable (residual cognition), we ran 10,000 simulations to derive 10,000 simulated test statistics.
Finally, we calculated the empiric p value for the observed test statistic based on the simulated test statistics, to assess whether the
overall association between DLGAP2 region’s methylation pattern and residual cognition deviates from the simulated null
distribution.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed as described in the STAR Methods. Analyses were performed in R, METAL and GWAF.
Behavioral data were checked for normality with Q-Q plots and Shapiro Wilk testing; data were log-transformed to ensure normality
for statistical analysis and QTLmapping. Relevant statistical analyses and n sizes are reported in figure legends and Results section.
Data values reported in both the main text and figure legends are given as mean ± standard error of the mean unless otherwise
stated.
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Table S1. Related to Figure 1: Distribution of spine type by age. Spine density and percentage 
of each spine type observed at either 6 months (m), 12 m, or 18 m in a subset of DO mice (n = 
55). No effect of age was observed on total spine density [ANOVA F(2, 52) = 1.0, p = 0.4] or on 
distribution of spine type [Chi-square test; χ2 (4, n = 55) = 2.4, p = 0.6]. 
 
Spine Type 6 m 12 m 18 m 
Stubby 31.2 28.9 24.6 
Thin 63.6 64.7 65.6 
Mushroom 5.2 6.4 9.8 
Total Density  
(# spines/10 μm) 
9.3 10.0 11.3 
Table S2. Related to Figure 2: Top GWAS hits within the DLGAP2 region from Jansen et 
al. (2019). Single nucleotide polymorphisms within the DLGAP2 region (± 50Kb) were evaluated 
for association with clinical Alzheimer’s dementia using published data from a cohort of 
individuals with European ancestry (Jansen et al. 2019). Under direction, “-” indicates protective 
effect, “+” indicates risk, “?” indicates not present. 
 
SNP P-value Nsum Neff Dir MAF Beta SE 
rs2957061 3.59E-05 71639 71639 ?-?- 0.44 -0.022 0.005 
rs2972183 3.66E-05 71639 71639 ?-?- 0.44 -0.022 0.005 
rs4433174 4.40E-05 71639 71639 ?-?- 0.43 -0.022 0.005 
rs2957059 4.42E-05 71639 71639 ?-?- 0.44 -0.022 0.005 
rs2972180 5.53E-05 71639 71639 ?-?- 0.42 -0.022 0.005 
rs2977182 7.67E-05 71639 71639 ?+?+ 0.48 0.021 0.005 
rs2957060 1.07E-04 71639 71639 ?+?+ 0.48 0.020 0.005 
rs73490628 2.13E-04 403592 402286 ??+- 0.021 0.029 0.008 
rs56066830 3.40E-04 17477 17477 ???+ 0.026 0.120 0.033 
rs571506119 4.12E-04 386906 386906 ??-? 0.0009 -0.132 0.037 
rs139482790 4.83E-04 387096 387096 ??+? 0.00009 0.413 0.118 
rs145185101 5.04E-04 386879 386879 ??+? 0.00049 0.178 0.051 
rs550396507 5.71E-04 386548 386548 ??+? 0.0017 0.095 0.028 
rs571859582 5.71E-04 386549 386549 ??+? 0.0017 0.096 0.028 
 
Abbreviations: SNP: single nucleotide polymorphism, Nsum: total sample size, Neff: effective 
sample size [= 4 / (1 / Ncases + 1 / Ncontrols)], Dir: Directionality, MAF: Minor allele frequency, 
SE: standard error 
  
Table S3. Related to Figure 2: Top 10 GWAS hits within the DLGAP2 region from African 
American GWAS. Single nucleotide polymorphisms within the DLGAP2 region (± 50Kb) were 
evaluated for association with clinical Alzheimer’s dementia using unpublished data from a 
cohort of individuals with African ancestry (Kunkle et al. 2019, pending submission). Under 
direction, “-” indicates protective effect of the minor allele compared to the major allele, “+” 
indicates risk, “?” indicates not present. 
. 
Variant P-value Dir Beta SE 
8:1316870 9.19E-05 +-----?---???- -0.86 0.22 
8:927728 0.0002 ---+--?----++- -0.15 0.04 
8:1313008 0.0003 -+++++?+++???- 0.80 0.22 
8:936158 0.0003 ---+-+------?- -0.50 0.14 
8:855450 0.0004 +-+-++++++-+ 0.48 0.14 
8:778641 0.0005 ++++++++++?--+ 0.49 0.14 
8:843935 0.0005 ---+------?++- -0.49 0.14 
8:772060 0.0005 ++++++++++?--+ 0.49 0.14 
8:1405507 0.0005 --+--------- -0.61 0.18 
8:1685397 0.0006 ++++++++++?+++ 0.33 0.10 
 
Abbreviations: Dir: Directionality, SE: standard error 
 
Table S4. Related to Figure 2: DLGAP2 differential expression across brain regions. Differential expression analysis comparing expression of 
DLGAP2 (Ensembl Gene ID: ENSG00000198010/HGNC symbol: Dlgap2) in Alzheimer’s dementia patients to controls (comparison: AD-Control 
in all cases) across multiple brain regions.  
 
 
Abbreviations: LogFC: log fold change, CI: confidence interval, Av. Expr: average expression 
 
 
Tissue LogFC CI.L CI.R Av. Expr T P.value Adj. P β Direction Study 
Cerebellum -0.28 -0.47 -0.08 -1.24 -2.82 0.005 0.02 -2.58 Down Mayo 
Temporal Cortex -0.33 -0.53 -0.14 -1.24 -3.33 0.0009 0.004 -1.19 Down Mayo 
Frontal Pole (BA10) -0.02 -0.11 0.07 5.11 -0.43 0.66 0.88 -6.06 None MSSM 
Superior Temporal Gyrus (BA22) -0.12 -0.23 -0.01 5.11 -2.22 0.03 0.16 -3.74 Down MSSM 
Parahippocampal Gyrus (BA36) -0.23 -0.34 -0.12 5.11 -4.21 2.85E-05 0.004 2.13 Down MSSM 
Inferior Frontal Gyrus (BA 44) -0.13 -0.23 -0.02 5.11 -2.34 0.02 0.20 -3.41 Down MSSM 
Table S5. Related to Figure 2: Association between DLGAP2 levels and non-Alzheimer’s 
disease neuropathology. DLPFC expression of DLGAP2 was compared to semi-quantitative 
measures of non-Alzheimer’s pathology across the ROS/MAP cohort. All were assessed using 
binary logistic regression or proportional odds models covarying for age at death and sex. 
 
Non-AD Neuropathology Beta SE T P-value 
Cerebral Amyloid Angiopathy -0.048 0.073 -0.662 0.51 
Cerebral Atherosclerosis 0.005 0.072 0.067 0.95 
Arteriolosclerosis -0.045 0.069 -0.642 0.52 
Lewy Bodies -0.061 0.100 -0.614 0.54 
Gross Infarctions (in Cortex) -0.100 0.098 -1.022 0.31 
Gross Infarctions (Anywhere) -0.086 0.080 -1.073 0.28 
Chronic Microinfarcts -0.141 0.089 -1.592 0.11 
 








Figure S1. Related to Figure 1: Allele effect interactions with age and SNP association 
mapping at the Dlgap2 QTL peak marker. A) Founder allele effect on working memory at the 
Dlgap2 region separated by age group. B) Interaction plot demonstrating allele effect x age 
interactions for each founder allele. C) Founder allele effect on working memory at the Dlgap2 
haplotype region separated by founder allele and age. Dotted black line denotes the location of 
the QTL peak marker. D) SNP association mapping using variants segregating the diversity 
outbred population identified by Sanger revealed 3 significant intronic SNPs and 1 structural 
variant in the Dlgap2 locus. The SNP at chr 8, 14.36131Mbp was high confidence, while the two 
SNPs positioned at chr 8, 14.41273 Mbp and 14.49918Mbp were noted as low confidence SNPs. 
The structural variant was noted as a deletion between position 14.604700Mbp and 






Figure S2. Related to Figure 1: Spine density or type does not correlate to working memory 
at either 6 or 12 months of age. A) Spine density (# spines/10 μm) across a subset of 6-month-
old DO mice did not significantly correlate to working memory function as measured by 
percentage of correct transitions in the T-maze. Neither did B) percentage of thin spines, C) 
percentage of stubby spines, nor D) percentage of mushroom spines. E-H) No significant 
correlations were observed between the same measures at 12 months of age.  
 
 Figure S3. Related to Figure 2: DLGAP2 SNP association, DNA methylation and protein 
expression in humans. A) Previously published GWAS data from individuals with European 
ancestry (Jansen et al. 2019) was used to evaluate the association between SNPs within the 
Dlgap2 region (± 50Kb) and clinical Alzheimer’s dementia. B) Across 10 datasets used in our 
meta-analysis, chr8:1316870 showed consistent association with increased risk for clinical 
Alzheimer’s dementia after adjustment for age, sex, and principal components of ancestry-
informative markers.  C) The observed association of each CpG within the DLGAP2 region with 
residual cognition was plotted as a quantile-quantile plot, along with the confidence intervals (CI) 
derived from 10,000 simulated association statistics. Observed associations were stronger than 
simulated test results (Fisher’s method; p=0.038), indicating that the DNA methylation pattern 
from the DLGAP2 region is associated with residual cognition. D) Across the ROS/MAP cohort, 
lower protein levels of DLGAP2 in the dorsolateral prefrontal cortex (DLPFC) were associated 
with higher annual cognitive decline (β = 0.29, p = <0.001). 
